Company intelligence / Profile preview

Union BioMedical

Hellerup, Denmarkuau.edu ↗

Ownership: Private
Development stage: Other

Overview

UNION Therapeutics develops novel treatments within immunology. Its lead candidate, orismilast—a next-generation PDE4 inhibitor—has shown promising efficacy and safety across multiple inflammatory skin diseases. The current focus has shifted toward hidradenitis suppurativa due to strong mechanistic fit and clinical results indicating efficacy at least comparable with biologic therapies along with unique pain reduction benefits. Orismilast may also address metabolic syndrome comorbidities common in these patients.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Union BioMedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Union BioMedical.

Explore the full profile